Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

GW Pharma receives Czech approval for Sativex spray for MS

GW Pharma receives Czech approval for Sativex spray for MS

GW Pharmaceuticals (LON:GWP) this morning said its cannabis-derived spray has been approved in the Czech Republic for patients with multiple sclerosis.

After a protracted regulatory sign off her in the UK, Sativex was given the green light in six other European countries including Germany, Italy and Sweden last month under an EU mutual recognition pact.

Launch timing in each country will be dependent on national regulations concerning pricing and reimbursement. 

GW's marketing partner, Almirall, anticipates Sativex will launch in Germany, Denmark and Sweden before the year-end.

The endorsement of its efforts came earlier this week when it unveiled a landmark agreement with Novartis to sell the product in a number of overseas markets.

City broker Peel Hunt said GW could not have chosen a better partner than the Franco-Swiss drugs giant. 

Novartis recently gained US and European regulatory approval for the first oral MS treatment, Gilenya, which analysts believe could make $3 billion in peak annual sales.

Setting a 178 pence a share price target, Peel Hunt analyst Paul Cuddon told investors: “(We) see an excellent buying opportunity given the recent share price weakness.”

In the year to date the shares have fallen 6 per cent and closed last night at 108.5 pence, valuing the GW at £143 million. 

Sativex is currently undergoing phase III clinical development for the treatment of cancer pain.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

cannabis leaf and green tablets
October 29 2018
The company will now proceed with stage II of the human clinical trial.
Laboratory testing
October 09 2018
Fifteen patients have been enrolled in the trial being carried out at Children’s Hospital of Philadelphia in the USA.
August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use